Optimal active immunotherapy of cancer should involve selectively potentiating the immune response to cancer specific antigens while reducing reactivity to self-antigens. Vaccine approaches are most likely to be effective in the setting of minimal cancer burden such as would occur after stem cell transplant (SCT). Therefore, the long-term goals of this project are to improve the effectiveness of SCT of hematopoietic neoplasms by safely increasing the immune response specifically directed at residual cancer cells using peptide vaccination. Much of the proposal focuses on WT1, a validated, commonly expressed tumor antigen. We also explore as a target the newly described mutated JAK2 kinase, responsible for many myeloproliferative disorders/These goals are reasonable because: 1) new understanding of the role of amino acid anchor motifs for MHC molecules in our target peptides and the strategic use of synthetic, heteroclitic, analog T cell epitopes. 2) the characterization of several peptide based vaccines for patients, including those to bcr/abl, WT-1, PR-1, and other oncogene associated targets as new cancer and leukemia associated tumor antigens. 3) the observation of clinical responses with the use of these peptide vaccines in patients with residual leukemia. Therefore, in this grant proposal we plan to extend our own work from the prior grant period and build on the published work of others into a better understanding of, and development of, specific immunotherapies directed to the oncogene products WT-1 and, for the first time, mutated JAK2 kinase. Previuosly, we focused on bcr/abl as a prototype target for vaccine therapy of CML and have progressed to multicenter trials. We build on this success here in new models directed at vaccine development against other important oncogene products.
Aims 1 and 2 focus on WT1, a validated vaccine target found in many tumors and leukemias.
Aim 1 is centered on discovery and characterization of novel WT-1 antigens.
Aim 2 A seeks to translate this knowledge in animals, in models of SCT and GVHD, and Aim 2B examines these antigens in humans.
Aim 3 looks at the newly discovered, mutated JAK2 kinase, responsible for many myeloproliferative disorders, as a potential malignancy-specific target. There are important synergies between this project and project #4 of Richard O'Reilly in the development of the WT1 vaccine strategies. Relevance: Vaccines inducing or augmenting leukemia-selective T cell responses may reduce risk of relapse post transplant.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Boudreau, Jeanette E; Hsu, Katharine C (2018) Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned. Trends Immunol 39:222-239
Lin, Richard J; Ho, Caleb; Hilden, Patrick D et al. (2018) Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations. Br J Haematol :
Malard, Florent; Labopin, Myriam; Cho, Christina et al. (2018) Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC. J Hematol Oncol 11:127
Luduec, Jean-BenoƮt Le; Kudva, Anupa; Boudreau, Jeanette E et al. (2018) Novel multiplex PCR-SSP method for centromeric KIR allele discrimination. Sci Rep 8:14853
Shah, Gunjan L; Moskowitz, Craig H (2018) Transplant strategies in relapsed/refractory Hodgkin lymphoma. Blood 131:1689-1697
Avanzi, Mauro P; Yeku, Oladapo; Li, Xinghuo et al. (2018) Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. Cell Rep 23:2130-2141
Staffas, Anna; Burgos da Silva, Marina; Slingerland, Ann E et al. (2018) Nutritional Support from the Intestinal Microbiota Improves Hematopoietic Reconstitution after Bone Marrow Transplantation in Mice. Cell Host Microbe 23:447-457.e4
Velardi, Enrico; Tsai, Jennifer J; Radtke, Stefan et al. (2018) Suppression of luteinizing hormone enhances HSC recovery after hematopoietic injury. Nat Med 24:239-246
Moskowitz, Craig H (2018) Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily. Blood Adv 2:821-824
Kim, Seong Jin; Huang, Yao-Ting; Foldi, Julia et al. (2018) Cytomegalovirus resistance in CD34+ -selected hematopoietic cell transplant recipients. Transpl Infect Dis 20:e12881

Showing the most recent 10 out of 452 publications